Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Telmisartan × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Ovarian Neoplasms 1 Breast Neoplasms 1

Interventions

enzalutamide 83 Magnetic Resonance Spectroscopy 82 Specimen Handling 63 Prednisone 63 Abiraterone Acetate 60 apalutamide 52 Androgen Antagonists 50 Radiosurgery 49 Leuprolide 47 Radiotherapy 44 Docetaxel 41 darolutamide 39 abiraterone 35 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30 Pluvicto 30 Biopsy 29 Radiation 28 Goserelin 27 pembrolizumab 26 gallium 68 PSMA-11 25 Triptorelin Pamoate 24 relugolix 23 bicalutamide 22 Surveys and Questionnaires 22 Standard of Care 22 Brachytherapy 22 Gonadotropin-Releasing Hormone 21 Carboplatin 20 cabazitaxel 19 olaparib 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06168487 2025-08-21

Telmisartan in Prostate Cancer

Dartmouth-Hitchcock Medical Center

Phase 1 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡